[Importance of anthracyclines in tumors of the ovary and endometrium and soft tissue sarcomas].
Anthracyclines, especially Adriamycin stand as a major progress in cancer chemotherapy: in ovarian carcinoma anthracyclines are combined to cyclophosphamide and cisplatin to obtain a rapid and complete remission; in endometrial carcinoma Adriamycin is the most active drug for palliative treatment; in soft-tissue sarcomas, anthracyclines in combination with other drugs give 15 to 65% response rates (8 months of median duration) in metastatic situation; except in one study (NCl), all adjuvant studies with these drugs are actually negative.
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin
Intérêt des anthracyclines dans les tumeurs de l'ovaire, de l'endomètre, les sarcomes des parties molles.